Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818165 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases
A Phase 1 study, sponsored by Sorrento Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03818165: Clinical Trial Phase 1 study, sponsored by Sorrento Therapeutics.
NCT03818165 is a Phase 1 study that was terminated before completion, run by Sorrento Therapeutics. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03818165, a Phase 1 study, was terminated before completion, sponsored by Sorrento Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.
Primary Outcome
As a measure of activity, Overall Survival (OS) will be assessed. The events for the assessment of OS are death events. Time to event endpoints will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where applicable.
Interventions
- BIOLOGICAL CAR2 Anti-CEA CAR-T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2021-05-21 |
| Phase | Phase 1 |
Why NCT03818165 stopped before completion
NCT03818165 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which CAR2 Anti-CEA CAR-T cells is the first listed.
NCT03818165 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03818165 about?
NCT03818165 is a clinical study titled "Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases". This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.
What is the current status of trial NCT03818165?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-07-29. Estimated completion is 2021-05-21.
What interventions are being tested in trial NCT03818165?
The interventions under investigation include: CAR2 Anti-CEA CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03818165?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03818165's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI